Using genetic information to predict health risks in young cancer survivors
Treatment-specific genetic risk scores for late effects prediction in childhood,adolescent, and young adult cancer survivors
This study is looking at how we can use genetic information to better understand the long-term health risks for people who survived cancer as kids or young adults, helping to spot those who might need extra care down the road.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10665850 on NIH RePORTER |
What this research studies
This research investigates how genetic risk scores can be tailored to predict long-term health risks in survivors of childhood, adolescent, and young adult cancers. The study aims to develop a new method that incorporates the effects of specific cancer treatments on genetic risks, which has not been done before. By analyzing a range of chronic health conditions, including subsequent cancers and cardiovascular diseases, the research seeks to create more accurate predictors of health risks for these survivors. This approach could help in identifying individuals at higher risk for late effects, allowing for better monitoring and preventive care.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have survived childhood, adolescent, or young adult cancer and are at risk for late effects.
Not a fit: Patients who have not survived cancer or those who are not within the childhood to young adult age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved health monitoring and preventive strategies for young cancer survivors, reducing their risk of developing chronic health conditions.
How similar studies have performed: While the use of polygenic risk scores is established in the general population, this specific approach to incorporate treatment-specific effects in cancer survivors is novel and has not been extensively tested.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Im, Cindy — University of Minnesota
- Study coordinator: Im, Cindy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.